ABP-745
/ Jiangsu Atom Bioscience and Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 14, 2024
ABP-745-101: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=126 | Recruiting | Sponsor: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
New P1 trial • Gout • Inflammatory Arthritis • Rheumatology
1 to 1
Of
1
Go to page
1